So, Nextech Invest, these Swiss guys, they threw another $6 million at Relay Therapeutics. Six million! Like it’s pocket change. And everyone’s getting all excited. “Institutional investor makes a bet!” A bet? It’s a stock. It either goes up or down. It’s not like they’re betting on a horse race, although, frankly, sometimes it feels that way with these biotech companies.
They bought 855,097 shares. 855,097! Who even counts that high? It’s just…excessive. And now, suddenly, Relay is 3.9% of Nextech’s portfolio. 3.9%! It’s not a commitment, it’s a…a flirtation. Like, “Oh, we’ll just see how this goes.” It’s infuriatingly non-committal.
Look at what they really like. Revolution Medicines – RVMD. $605.43 million. 58.5% of their entire portfolio. That’s a relationship. That’s a guy who’s picked a stock and is sticking with it. The rest are just…accessories. TYRA, TNGX, ORIC, ZYME… it’s like a dating app profile. “Here are my options.”
And Relay? Up 197% in a year. Of course. Everything goes up for a while. It’s the staying up that’s the problem. And they’re beating the S&P 500 by 181 percentage points. Fine. Great. But that’s just math. It doesn’t mean it’s a good investment. It just means the S&P 500 had a particularly bad year.
Let’s look at the numbers, because that’s what we’re supposed to do. Price: $9.93. Okay. Market cap: $1.77 billion. Not nothing, but not exactly Amazon. Revenue: $15.4 million. And net income? Negative $276.5 million. So, they’re losing money. A lot of money. But it’s biotech. Apparently, that’s acceptable. You just burn through cash until you…what? Discover a miracle drug? It’s a gamble, plain and simple. And everyone pretends it’s science.
They’re developing “precision medicines.” Of course they are. Everyone’s developing “precision” everything these days. It’s just a buzzword. They have some candidates, RLY-4008 and RLY-2608. Sounds like robot models. And they’re using “computational modeling.” Which means they’re letting computers make decisions. What could possibly go wrong?
So, Nextech throws $6 million at this, and everyone acts like it’s some kind of revelation. It’s not. It’s a Swiss fund making a small bet on a company that’s losing a ton of money. But it’s a clinical-stage biotech company, so it’s different. It’s like saying, “Well, they haven’t actually sold anything yet, but they’re working on selling something, so it’s okay.” It’s circular logic.
If you’re looking for exposure to oncology, just buy an ETF. XBI or IBB. It’s less exciting, less glamorous, but it’s also less likely to leave you holding the bag when the inevitable happens. Or, you know, just don’t invest. It’s an option. A perfectly valid option.
But no, everyone has to chase the next big thing. The next miracle drug. The next stock that’s going to “disrupt” everything. It’s exhausting. And frankly, a little bit insulting. Like we’re all supposed to be experts in molecular biology or something. I just want a stock that goes up consistently. Is that too much to ask?
Read More
- Spotting the Loops in Autonomous Systems
- Seeing Through the Lies: A New Approach to Detecting Image Forgeries
- Staying Ahead of the Fakes: A New Approach to Detecting AI-Generated Images
- Julia Roberts, 58, Turns Heads With Sexy Plunging Dress at the Golden Globes
- Unmasking falsehoods: A New Approach to AI Truthfulness
- Gold Rate Forecast
- Palantir and Tesla: A Tale of Two Stocks
- The Glitch in the Machine: Spotting AI-Generated Images Beyond the Obvious
- How to rank up with Tuvalkane – Soulframe
- TV Shows That Race-Bent Villains and Confused Everyone
2026-03-19 22:02